Drug Combination Details

General Information of the Combination (ID: C43311)
Name Bufalin   NP Info  + Osimertinib   Drug Info 
Structure +
Disease
Lung cancer [ICD-11: 2C25]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Reversing Drug Resistance by This Combination
                 Reversing Drug Resistance     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Down-regulation Expression MCL1  Molecule Info 
Pathway MAP
                    In-vitro Model HCC827 CVCL_2063 Lung adenocarcinoma Homo sapiens
PC-9 CVCL_B260 Lung adenocarcinoma Homo sapiens
                    In-vivo Model Male BALB/c nude mice (4-6 weeks old, 18-22 g) were injected subcutaneously in the rear flank with 4 * 106 PC-9OR cells.
                    Experimental
                    Result(s)		 Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer.
References
Reference 1 Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. Toxicol Appl Pharmacol. 2019 Sep 15;379:114662.
 Download Picture         KEGG Link